Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden immune fire: could CMV or autoimmunity be fueling HIV-Related inflammation?

NCT ID NCT04067869

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why certain immune cells (CD4 and CD8 T cells) remain activated in people with HIV whose viral load has been undetectable on antiretroviral therapy for at least two years. Researchers are investigating whether a common virus called cytomegalovirus (CMV) or an autoimmune process might be causing this ongoing activation. The study involves blood samples from about 392 participants and measures activation markers on immune cells. The goal is to better understand what drives chronic inflammation in well-treated HIV infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If this study identifies key drivers of immune activation, it could point toward new ways to reduce inflammation and improve long-term health in people with HIV.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any therapy, and results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

392 people

The number who actually took part.

Started

Feb 2010

Finished

Dec 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients included in the Aquitaine ANRS CO3 cohort aged 18 years or older (confirmed HIV-1 infection and at least one follow-up in the cohort), * plasma HIV-1 RNA \<50 copies / ml for at least 24 months under a highly active antiretroviral combination (treatment comprising at least 3 antiretroviral drugs) modified or initiated between 2005 and 2008, * Follow-up in one of the departments of Bordeaux University Hospital or Libourne Hospital, * Free, informed and written consent, signed by the patient and the investigator (Consent of the Aquitaine CO3 Cohort and linked to this specific study). Exclusion Criteria: * Presence of 2 consecutive measurements of HIV RNA\> 50 copies / ml, * History of immunotherapy treatments (interleukin-2), * Hepatitis B or C co-infections, * Pregnancy * Breastfeeding * Symptomatic infectious episode in progress.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus infections HIV-1-infection

Contacts and locations

Locations

  • Study site

    Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.